Authors' objectives: factor receptor 2 (VEGFR2) and RET. MET plays a key role in cellular proliferation, migration and angiogenesis, and is mutationally activated in various tumour types. Overexpression of VEGF and MET has been observed in a number of different cancers, including renal cell carcinoma. Cabozantinib is intended to treat metastatic renal cell carcinoma (RCC). In 2012, there were 7,366 new cases of kidney cancer registered in England. RCC accounts for 80-90% of kidney cancers in the UK and clear cell RCC is the most frequent subtype of sporadic RCC in adults (70-85%). It is estimated that 57% of patients presenting each year have stage I or II RCC, and 29% of these are expected to progress to stage III each year. Ten-year survival rates from kidney cancer in England and Wales have almost doubled in the last 40 years. In 2013-14, there were 13,829 hospital admissions for kidney cancer equating to 62,572 bed days and 16,631 finished consultant episodes in England. In 2013, 3,312 deaths from renal cancer were registered in England and Wales. Surgical intervention remains the standard of care for localised or locally advanced RCC and guidelines suggest that surgery should also be considered when metastatic disease is present, although a laproscopic approach may be considered. In those with limited volumes of metastatic disease and large primary tumours, as well as a good Karnofsky performance status, cytoreductive nephrectomy is recommended. First line drug therapy may include sunitinib and pazopanib, but axitinib is the only NICE approved drug for second line therapy after failure with a first line tyrosine kinase inhibitor. Cabozantinib is currently in a phase III trial comparing its effect on progression free survival against treatment with everolimus. This trial is expected to complete in August 2016.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/cabozantinib-cometriq-for-metastatic-renal-cell-carcinoma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Centre (NIHR HSC)